Therapeutic potential of targeting PCLAF in endometrial cancer: Insights from Wnt/β-catenin and P53 regulatory mechanisms
In conclusion, our findings suggest that silencing PCLAF hinders EC progression by suppressing the Wnt/β-catenin pathway and activating the p53 signaling pathway. This insight suggested that targeting PCLAF may offer a new therapeutic avenue for EC treatment.
Authors
- Yijuan Xing
- Yongxiu Yang (ORCID: https://orcid.org/0000-0002-1449-4326)
- Wenhua Wang (ORCID: https://orcid.org/0000-0001-9274-5402)
- Xi Chen (ORCID: https://orcid.org/0009-0006-4574-6166)
Institutions
- First Hospital of Lanzhou University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Biochemical and Biophysical Research Communications
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1016/j.bbrc.2025.152092
- Primary Topic
- Wnt/β-catenin signaling in development and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00